(Q27690869)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23074309%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

meta-analysis

0 references

title

The relative efficacy of boceprevir and telaprevir in the treatment of hepatitis C virus genotype 1 (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23074309%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23074309%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

Cathal Walsh

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23074309%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

author name string

Susanne Schmitz

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23074309%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

Aisling O'Leary

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23074309%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

Colm Bergin

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23074309%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

Suzanne Norris

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23074309%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

Michael Barry

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23074309%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

language of work or name

English

0 references

publication date

16 October 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23074309%20AND%20SRC:MED&resulttype=core&format=json

Clinical Infectious Diseases

15 February 2020

published in

2 references

PubMed

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23074309%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

volume

56

2 references

PubMed

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23074309%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

issue

2

2 references

PubMed

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23074309%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

page(s)

228-235

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23074309%20AND%20SRC:MED&resulttype=core&format=json

The changing epidemiology of hepatitis C virus infection in Europe

15 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS880

Global epidemiology of hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS880

EASL Clinical Practice Guidelines: management of hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS880

An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS880

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS880

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS880

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS880

Boceprevir and telaprevir in the management of hepatitis C virus-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS880

Boceprevir for untreated chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS880

Boceprevir for previously treated chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS880

Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS880

Telaprevir for previously untreated chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS880

Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS880

Telaprevir for previously treated chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS880

Telaprevir for retreatment of HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS880

Telaprevir and peginterferon with or without ribavirin for chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS880

Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS880

Bayesian methods for evidence synthesis in cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS880

Combination of direct and indirect evidence in mixed treatment comparisons

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS880

A mixed treatment comparison of the efficacy of anti-TNF agents in rheumatoid arthritis for methotrexate non-responders demonstrates differences between treatments: a Bayesian approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS880

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS880

Using mixed treatment comparisons and meta-regression to perform indirect comparisons to estimate the efficacy of biologic treatments in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS880

21 January 2018

Identifiers

DOI

10.1093/CID/CIS880

2 references

Consolidated OpenCitations Corpus – April 2017

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23074309%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

1 reference

Consolidated OpenCitations Corpus – April 2017

2 references

Consolidated OpenCitations Corpus – April 2017

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23074309%20AND%20SRC:MED&resulttype=core&format=json